Peptides Similar to OS-01 (Peptide 14)
Compare OS-01 (Peptide 14) with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •FOXO4-DRI: undefined
- •Epitalon: undefined
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| OS-01 (Peptide 14) (current) | - | - |
| FOXO4-DRI | ||
| Epitalon | ||
| GHK-Cu |
Overview#
OS-01 (Peptide 14) belongs to the emerging class of senotherapeutic compounds -- agents that target cellular senescence for anti-aging effects. Several other peptides address aging through related but distinct mechanisms. Understanding these differences is important for evaluating the landscape of anti-aging peptide research.
Detailed Comparisons#
OS-01 vs FOXO4-DRI#
These two peptides represent the two major strategies for targeting cellular senescence:
| Feature | OS-01 | FOXO4-DRI |
|---|---|---|
| Mechanism | Senomorphic (PP2A modulation) | Senolytic (p53-FOXO4 disruption) |
| Action | Prevents senescence progression | Triggers apoptosis in senescent cells |
| Administration | Topical | Injectable |
| Size | 10 amino acids | 24 amino acids (D-retro-inverso) |
| Availability | Commercial cosmetic product | Research use only |
| Clinical trials | 3 published (2024-2025) | None published |
| Target tissue | Skin (topical) | Systemic (preclinical) |
OS-01's senomorphic approach is inherently more conservative -- it supports cellular repair rather than eliminating cells. FOXO4-DRI's senolytic mechanism is potentially more powerful but carries greater theoretical risk from immune activation during senescent cell clearance.
OS-01 vs Epitalon#
Both peptides target aging at the cellular level but through entirely different pathways:
| Feature | OS-01 | Epitalon |
|---|---|---|
| Mechanism | PP2A modulation, senescence reduction | Telomerase activation |
| Primary target | Senescent cell burden | Telomere length |
| Administration | Topical | Injectable |
| Research stage | Published clinical trials | Primarily preclinical (Khavinson studies) |
| Commercial status | Available as cosmetic product | Research chemical |
| Evidence independence | All OneSkin-sponsored | Primarily from one research group |
Both compounds share a limitation in that the majority of published research comes from a single research group or company, limiting the strength of the evidence base.
OS-01 vs GHK-Cu#
Both peptides are used in topical anti-aging applications but work through different mechanisms:
| Feature | OS-01 | GHK-Cu |
|---|---|---|
| Mechanism | PP2A modulation, senescence reduction | Copper-dependent collagen synthesis, wound healing |
| Molecular type | Synthetic decapeptide | Tripeptide-copper complex |
| Primary effects | Senescence marker reduction, barrier function | Collagen remodeling, antioxidant activity |
| Research history | Published since 2023 | Studied since 1970s |
| Availability | OneSkin products only | Widely available from multiple suppliers |
| Sequence disclosure | Proprietary | Publicly known (GHK) |
GHK-Cu has a substantially longer research history and an openly known structure, allowing independent study by multiple research groups. OS-01 is newer with a proprietary sequence but targets a more specific mechanism (senescence) that is increasingly recognized as central to skin aging.
Key Differentiators for OS-01#
OS-01 is unique among anti-aging peptides in several respects:
- First senotherapeutic peptide available in commercial products
- Only peptide with published RCT data specifically measuring senescence-related skin outcomes
- Senomorphic mechanism (cell preservation) rather than senolytic (cell elimination)
- Exclusively topical application with published evidence of systemic effects
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer